Ann: Trading Halt, page-41

First 41 Last

Share
Profile

Follow
HoganHound

1,422 Posts.

94

02/04/19

06:26

Post #: 37958108
Share

Originally posted by MrSiliconValley: ↑

Do you think with revenues for CY19 to be potentially ~$30 million (current pipeline, excluding new developments) and a market cap of $75 million is crazy or "flying way ahead of its revenues"? The statement of "A lot of capital has been issued and has not translated into sales" is just false. They not even few months ago signed a $12.6 million dollar contract. They had their largest cash receipts quarter in the latest quarter.

To be completely fair, the market value of the company is at an all time high in the company's history. This wouldn't be the case without the acquisitions and lane switch into the current business activities (AI, Blockchain, Health, Marketing).

I'm surprised there's not more speculation. There are specs on the ASX with less than $5 million in annual revenues and report $10 million plus losses yet have major speculation baked in with $200m - $400m market caps.

I understand where you're coming from on the issue with cash-flows and no longer having to report quarterly but as a shareholder I'd prefer to see half-years. Share price movement is too volatile during quarterly releases and a half-yearly gives a better picture of the business as a whole as payments (especially in the mobile apps buinsess) can carry over into the next quarter. At the end of the day, the institution of ASX has made a decision to relieve AB1.

Expand

is it confirmed that they will not report a quarterly just because they got their relief?

just because you can does not mean you will i am not sure it would be of benefit

AB1 Price at posting: 10.0¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

IRE

Iress runs 'hot' for Wealth Within's stock tips

LU7

Strong PFS numbers solidify Lithium Universe's big plans for Québec

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Failure to report prompts ASX to impose multiple company suspensions

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals